FDA Issues Warning About Compounded Versions of Wegovy, Ozempic
The FDA does not review compounded drugs for safety, effectiveness, or quality; compounded medications are not FDA-approved
Diabetes Information Center
Recent 2023 FDA Approvals
Recent FDA approvals include treatments for chronic migraine, type 1 diabetes, blood cancers, tardive dyskinesia and chorea associated with Huntington disease, vasomotor symptoms of menopause, pain and fever, and Fabry disease.
Cancer Patients With Diabetes May Have Worse Outcomes on ICIs
Cancer patients with type 2 diabetes may have worse survival outcomes on immune checkpoint inhibitor therapy, a new study suggests.
FDA Clears iLet Bionic Pancreas for Patients With Type 1 Diabetes
The iLet Bionic Pancreas uses an adaptive closed-loop algorithm requiring only a user’s body weight for start-up and no additional insulin dosing parameters.
Get Moving: Prescribing Exercise to End Insulin Resistance
Afternoon high intensity exercise may have a greater effect on lowering blood glucose levels in patients with diabetes than morning high intensity interval training.
Residential Segregation Tied to Worse Type 1 Diabetes Outcomes in Black Youth
Findings persist even after controlling for adverse neighborhood conditions.
Substantial Weight Loss Reductions Observed With Tirzepatide in T2D Patients
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Sugar-Sweetened Beverage Intake Linked to Mortality, CVD in T2D
Increased hazard ratio noted for all-cause mortality, CVD incidence and mortality for higher sugar-sweetened beverage intake.
Macrovascular Complication Is Unaffected by Glucose Control Intensity in Diabetes
Researchers investigated the role of glucose control on multiple cardiovascular disease-related events in patients with type 2 diabetes.
COVID-19 Pandemic Increased Americans’ Concerns About Obesity
The researchers found that nearly 3 in 10 Americans became more worried about having obesity, with greater concern seen among Black and Hispanic Americans.
Improper Charging of FreeStyle Libre Readers Prompts Alert From Abbott
At this time, no readers are being recalled; customers should continue to use them with the Abbott-provided USB cable and power adapter.
Greater HbA1c, Weight Loss Reductions Seen With Oral Semaglutide at Higher Doses
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
Semaglutide and Tirzepatide: Top 5 Things Clinicians Should Know
Obesity experts discuss how semaglutide and tirzepatide are changing the treatment landscape and challenges affecting access including drug shortages, inappropriate prescribing, insurance coverage, and cost.
Autism May Be a Risk Factor for Cardiometabolic Diseases, Especially in Youth
Investigators from Texas Tech University searched publication databases for studies evaluating risk for diabetes mellitus, hypertension, dyslipidemia, and atherosclerotic macrovascular disease in the setting of autism spectrum disorder.
Dapagliflozin Lowers Cardiovascular Risks, Uric Acid Regardless of Gout Status
Latest findings are from a post hoc meta-analysis of pooled data from the DAPA-HF and DELIVER trials.
More than 60% of Adults With Type 1 Diabetes Have Overweight, Obesity
Those with type 1 diabetes are least likely to increase physical activity, reduce caloric intake to manage overweight or obesity.
Risk for Diabetes After COVID-19 Still Increased During Omicron Phase
Risk for new-onset diabetes significantly elevated during omicron-dominant phase, but no increase seen for risks for hypertension, hyperlipidemia.
SGLT2 Inhibitor Use in Case of Acute Decompensated Heart Failure With Edema
Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure.
Legislative Update: Diabetic Shoes and Injured Federal Workers Acts Introduced
Newly introduced bills aim to increase access to care for injured federal workers and therapeutic shoes for patients with diabetes.
We Have Better Obesity Medications, but Access Is Lagging
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Type 1 Diabetes Information Center
Loading... 
Loading...